KBC Group
ASND icon

KBC Group’s Ascendis Pharma A/S ASND Stock Holding History

KBC Group’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$81K Hold
356
– – ﹤0.01% 1445
2025
Q4 		$76K Hold
356
– – ﹤0.01% 1457
2025
Q3 		$71K Hold
356
– – ﹤0.01% 1478
2025
Q2 		$61K Sell
356
-55
-13% -$8.96K ﹤0.01% 1492
2025
Q1 		$64K Hold
411
– – ﹤0.01% 1712
2024
Q4 		$57K Hold
411
– – ﹤0.01% 1789
2024
Q3 		$61K Buy
+411
New +$55.5K ﹤0.01% 1618

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

KBC Group's ASND Position: Q1 2026 in Review

KBC Group held its Ascendis Pharma A/S (ASND) position steady in Q1 2026 at 356 shares worth $81K. The position accounts for ﹤0.01% of the portfolio, ranked #1445.

KBC Group first reported a position in ASND in Q3 2024 and has held it in 7 quarters since. 273 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

  • KBC Group held 356 shares of Ascendis Pharma A/S worth $81K as of Q1 2026.
  • KBC Group left its Ascendis Pharma A/S share count unchanged in Q1 2026.
  • Ascendis Pharma A/S made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1445 holding.
  • KBC Group first reported a position in Ascendis Pharma A/S in Q3 2024 and has held it in 7 quarters since.
  • 273 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.